We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mitochondrial Damage May Explain the Increased Incidence of Hypertension in Black Adults

By LabMedica International staff writers
Posted on 03 Mar 2022
Print article
Image: Monitoring blood pressure (Photo courtesy of 123rf.com)
Image: Monitoring blood pressure (Photo courtesy of 123rf.com)

Increased plasma concentration of the enzyme xanthine oxidase (XO) and the resulting mitochondrial DNA damage that it can cause may explain why Blacks have a significantly higher incidence of hypertension than their White counterparts.

Investigators at the University of Alabama (Birmingham, USA) had previously reported that increased plasma XO activity in patients with resistant hypertension could cause mitochondrial DNA damage and promote release of fragments called mitochondrial DNA damage-associated molecular patterns (mtDNA DAMPs). Xanthine oxidase is widely distributed in the heart, liver, gut, lung, kidney and brain, as well as in blood plasma. In its normal metabolic function, it generates oxygen radicals as a byproduct, including hydrogen peroxide and superoxide, which are reactive oxygen species that can damage DNA.

Considering that Black adults in the United States have one of the highest rates of hypertension in the world and have a 50% increased incidence of heart failure as compared to Whites, the investigators examined the importance of racial differences in XO activity and mtDNA DAMPs in adults with resistant hypertension.

The experimental cohort for this study included 91 resistant hypertension patients, 44% of whom were Black, and 37 controls with normal blood pressures. The resistant hypertension group all had blood pressures above 140/90 millimeters of mercury (mmHg), and all were on four or more medications for treatment of their high blood pressure.

Results revealed that Black resistant hypertension patients were younger (mean age 52±10 versus 59±10 years), with higher XO activity and left ventricular wall thickness, and worse diastolic dysfunction than White resistant hypertension patients. Urinary sodium excretion was positively related to left ventricular end-diastolic volume and left ventricular mass among Black but not White resistant hypertension patients. Patients with resistant hypertension had increased mtDNA DAMPs versus controls, with Black mtDNA DAMPS greater than Whites.

Transmission electron microscopy of skeletal muscle biopsies in resistant hypertension patients demonstrated mitochondrial damage such as cristae lysis, myofibrillar loss, large lipid droplets, and glycogen accumulation.

"Xanthine oxidase activation may set up a feed-forward cycle of mitochondrial damage, mitochondrial reactive oxygen species production, mtDNA DAMP release, and inflammation in the pathogenesis of hypertension end-organ injury," said senior author Dr. Louis J. Dell'Italia, professor emeritus of cardiovascular disease at the University of Alabama. "These results warrant a larger study that includes metabolic syndrome and xanthine oxidase as a potential therapeutic target to reduce mitochondrial damage and attenuate left ventricular diastolic dysfunction in Black adults with resistant hypertension. Although Black adults have the highest death rate for heart failure, they are consistently underrepresented in clinical trials. The greater heart failure burden among Black adults calls for further work to discover effective preventive and therapeutic strategies for this higher-risk population."

The study was published in the February 15, 2022, online edition of the journal Hypertension.

Related Links:
University of Alabama 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.